Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Reuters Investment Profile
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eisai Co Ltd announces initiation of phase 3 trial of Eribulin Mesylate Injection Versus Weekly Paclitaxel in first and second lines of metastatic breast cancer

Thursday, 27 Feb 2014 08:15am EST 

Eisai Co Ltd:Start of randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second line treatment for HER2-negative locally recurrent or metastatic breast cancer (MBC).Recruitment is active for this multicenter study, conducted in partnership with the Academic and Community Cancer Research United (ACCRU) group.Aims to enroll about 910 patients across the U.S. the primary endpoint is overall survival.Research study involves an investigational use of eribulin mesylate.Efficacy and safety of eribulin mesylate in first- and second-line MBC have not been established and this release is not intended to convey conclusions of efficacy and safety. 

Company Quote

153.0 +3.76%
20 Oct 2014